Grace Therapeutics (GRCE) Reports Q3 Loss of $2.3M, 14c EPS

Grace Therapeutics (GRCE) reported a net loss of $2.3 million in fiscal third quarter, ending February 3, 2026, with a loss of 14 cents per share. The result reflects continued investment in clinical trials and product development, with no revenue reported for the period.